Identification of Hub Genes Involved in Early-onset Schizophrenia: From Genetic Susceptibility to Predicted Regulated Gene Expression.

Background: Despite a high heritability of schizophrenia (SZ), only limited variance was attributed to gene loci or the polygenic risk score in genome-wide association studies (GWAS). Early-onset SZ, a more homogeneous SZ subtype, may aid in bridging the genotype-phenotype gap and the identification of its hub genes is critical for early intervention in clinical practice. We aimed to examine the gene expression risk score (GeRS) in patients from both multiplex and simplex families to identify hub genes for early-onset SZ, and perform enrichment analysis to understand the biological functions of the hub genes.

Abnormally low prolactin levels in schizophrenia patients after switching to aripiprazole in a randomized trial: a biomarker for rebound in psychotic symptoms?

Background: Switching to aripiprazole from other antipsychotics can avoid antipsychotic-induced hyperprolactinemia but may result in an abnormally low prolactin level. This study aimed to assess whether the aripiprazole-induced abnormally low prolactin level was a biomarker for subsequent rebound of positive symptoms in schizophrenia patients.

Methods: Participants were 63 patients in an 8-week trial of switching to aripiprazole, in which preswitching antipsychotics were maintained for the first 2 weeks and aripiprazole was fixed at 15 mg orally throughout the trial.